NEW YORK, NY (July 20, 2011) – Schrödinger announced today that it has signed a research agreement with Janssen Pharmaceutica NV (Janssen). Under the agreement, Schrödinger will bring its full suite of simulation tools, including the patented WaterMap technology and other algorithms that have yet to be productized, to bear in both lead discovery and lead optimization projects. The collaboration will be highly interactive involving medicinal chemists, biologists, and computational chemists from Janssen working closely with Schrödinger’s DDAG team. Schrödinger will receive collaboration fees, in addition to potential milestone payments under the terms of the agreement.

"We are very pleased to be working with Janssen and to add this to our growing portfolio of collaborations,” said Schrödinger’s President, Dr. Ramy Farid, “because with each new project, we always learn something new that in turn allows us to make continual improvements to our software.”

 

About Schrödinger

Schrödinger is a scientific leader in developing state-of-the-art chemical simulation software for use in pharmaceutical and biotechnology research. The Company provides products ranging from general molecular modeling programs to a full-featured suite of drug design software using both ligand- and structure-based methods. The predictive power of Schrödinger's software allows scientists to accelerate their research and development activities, reduce research costs, and make novel discoveries that might not be possible otherwise. Most recently, Schrödinger acquired the Seurat platform to add enterprise-wide data sharing and visualization to its complete offerings. Schrödinger operates from locations in New York, Oregon, California, Massachusetts, Maryland, Germany, the UK, and Japan. For more information, please visit www.schrodinger.com.

 

### 

Contact:
Shi-Yi Liu
+1 503 299 1150
Shi-Yi.Liu@schrodinger.com